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Research
AbstrACt
Objectives We piloted an intervention to determine if 
support from a case manager would assist adults being 
investigated for tuberculosis (TB) to link into TB and HIV 
care.
Design Pilot interventional cohort study.
Participants and setting Patients identified by primary 
healthcare clinic staff in South Africa as needing TB 
investigations were enrolled.
Intervention Participants were supported for 3 months 
by case managers who facilitated the care pathway by 
promoting HIV testing, getting laboratory results, calling 
patients to return for results and facilitating treatment 
initiation.
Outcomes measured Linkage to TB care was defined 
as starting TB treatment within 28 days in those with a 
positive test result; linkage to HIV care, for HIV-positive 
people, was defined as having blood taken for CD4 count 
and, for those eligible, starting antiretroviral therapy within 
3 months. Intervention implementation was measured by 
number of attempts to contact participants.
results Among 562 participants (307 (54.6%) female, 
median age: 36 years (IQR 29–44)), most 477 (84.8%) 
had previously tested for HIV; of these, 328/475 (69.1%) 
self-reported being HIV-positive. Overall, 189/562 (33.6%) 
participants needed linkage to care (132 HIV care linkage 
only; 35 TB treatment linkage only; 22 both). Of 555 
attempts to contact these 189 participants, 407 were to 
facilitate HIV care linkage, 78 for TB treatment linkage 
and 70 for both. At the end of 3-month follow-up, 40 
participants had not linked to care (29 of the 132 (22.0%) 
participants needing linkage to HIV care only, 4 of the 35 
(11.4%) needing to start on TB treatment only and 7 of the 
22 (31.8%) needing both).
Conclusion Many people testing for TB need linkage to 
care. Despite case manager support, non-linkage into HIV 
care remained higher than desirable, suggesting a need to 
modify this intervention before implementation. Innovative 
strategies to enable linkage to care are needed.
bACkgrOunD 
People being investigated for tubercu-
losis (TB) are not linking into TB and HIV 
care. Studies done in South Africa have shown 
that 11%–25% people with positive sputum 
results have ‘pre-treatment loss to follow-up’, 
defined as not starting on TB treatment either 
at all, or within a month of sputum submis-
sion.1–3 More recently the XTEND (Xpert 
for TB-Evaluating a New Diagnostic) trial, 
a pragmatic cluster-randomised controlled 
trial comparing smear microscopy versus 
Xpert MTB/RIF (a rapid and more sensitive 
assay) among adults being investigated for 
TB showed pretreatment loss to follow-up 
of 17%, not reduced by use of Xpert MTB/
RIF.4 Mortality at 3 and 6 months of sending 
sputum for microbiological investigation was 
3.2% and 5.0%, respectively.4 5 South Africa's 
guidelines recommend that all patients with a 
positive diagnosis for TB as well as those being 
investigated for TB be tested for HIV.6 The 
XTEND trial also showed that not being on 
ART and not knowing one’s HIV status were 
associated with an increased risk of death,4 
suggesting that for persons being investigated 
for TB and not already on antiretroviral treat-
ment (ART), linkage to HIV care is a priority.
Linking people with a positive HIV test 
result into HIV care has traditionally involved 
multiple steps, including undertaking a CD4 
count to determine eligibility for ART initia-
tion, with losses at each step.7 Furthermore, 
strengths and limitations of this study
 ► The study had a representative sample of adults 
being investigated for TB from five clinics in two 
provinces with diverse living conditions and repre-
sentative of urban as well as periurban setting.
 ► The intervention was well implemented with 555 
contact attempts made to participants needing link-
age to care.
 ► The lack of a ‘standard of care’ comparison group 
meant we could not formally determine if the strate-
gy made a difference or not.
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TB and HIV care are not fully integrated, making it diffi-
cult for patients needing treatment for TB and HIV to 
access care for both conditions. In an attempt to improve 
linkage into HIV care among HIV-positive patients, strat-
egies such as case management or health system navi-
gation, using strengths-based case management, where 
patients identify their strengths and use them to improve 
their circumstances, have been evaluated.8–10 One such 
study, a randomised control trial in the USA among 
recently diagnosed HIV-positive people supported by a 
case manager, showed that 78% in the intervention arm 
linked into care successfully compared with the 60% in 
the control arm.8 Task-shifting of duties such as TB coun-
selling, HIV counselling and testing and ART adherence 
counselling to lay counsellors has been used as a strategy 
to relieve short-staffed and overwhelmed healthcare 
workers in primary healthcare clinics (PHCs).11 In this 
study, we pilot tested an intervention using lay counsellors 
to provide support to adults being investigated for TB by 
following up with patients to ensure that they returned to 
clinic (1) to receive their TB and HIV-related test results; 
(2) to do follow-up tests and (3) to start appropriate treat-
ment. This was intended to overcome obstacles such as 
nurses not having enough time to follow-up patients and 
the difficulties of making contact with patients. The study 
objectives were to determine feasibility of implementing 
the intervention (determined by number of interactions 
made) and acceptability of the intervention (determined 
by a qualitative study, reported separately) and to esti-
mate linkage to TB and HIV care.
MethODs
study design
An interventional cohort study was designed to pilot-test 
case manager support at PHCs for adults being investi-
gated for TB to link them into HIV care and initiate TB 
treatment where these were clinically indicated. The study 
was conducted from September 2014 to April 2015 in six 
PHCs in Mpumalanga and Gauteng provinces, South 
Africa, which had previously participated in the XTEND 
trial and were selected on the basis of their high propor-
tions of pretreatment loss to follow-up during that trial. 
At the time of implementing the case manager study, 
South Africa’s criteria for ART initiation were a CD4 
count of ≤350 cells/mm3 or active TB at any CD4 count. 
Guidelines also suggested that following a TB diagnosis, 
ART should be initiated in HIV-positive persons within 
2 weeks after TB treatment initiation.
Description of case manager intervention
Case managers were lay counsellors, trained by investiga-
tors on basic TB and HIV education and national ART 
and TB management guidelines at the time. One case 
manager was placed at each of the six clinics. The roles of 
the case managers were: (1) to follow-up on sputum test 
results from the laboratory; (2) to call all patients to return 
to the clinic for their results; (3) to facilitate TB treatment 
start in patients with a positive sputum test result; (4) to 
encourage those with unknown HIV status or negative 
HIV test results older than 3 months at enrolment to test 
for HIV; and (5) for those who tested HIV-positive or 
knew themselves to be HIV-positive but did not know their 
CD4 count at enrolment, to facilitate CD4 count testing, 
follow-up on CD4 results from laboratory and to facilitate 
ART initiation if eligible. A study algorithm, based on the 
national TB management and ART guidelines, was devel-
oped to assist the study staff in guiding patients through 
the health system in seeking appropriate care (figure 1). 
Case managers attempted to contact participants at 
least once a week and continued with contact attempts 
until linkage to care was complete, or the end of study 
follow-up, 3 months after enrolment. Lists for weekly 
follow-ups of enrolled participants that needed linkage 
to care were maintained through the automated release 
of weekly follow-up case report forms by a smart phone 
application that was used to collect study data. Contact 
attempts were made to inform participants of the avail-
ability of their results as soon as they were received at the 
clinics, to remind participants of clinic appointments and 
to check if patients had returned to clinic for appropriate 
care. These attempts included inperson meetings at the 
clinic or telephonic calls. Contacts were categorised as 
successful if the case manager was able to meet with the 
participant or speak to the participant telephonically. All 
decisions about clinical management of participants were 
made by PHC staff according to their routine practice. 
Case managers were not actively involved in arranging 
any additional investigations for TB after enrolment.
study population and data collection
Participants were eligible for inclusion in the study, based 
on the criteria previously used in the XTEND trial: if they 
were aged ≥18 years, identified by PHC staff as needing 
investigation for TB through TB symptom screen as 
having any of the four TB symptoms, provided a sputum 
specimen for TB investigation, able to give informed 
consent, likely to remain in the study catchment area for 
8 months and able to provide adequate locator informa-
tion, including an alternative contact number for either a 
friend of family member. Case managers recruited partic-
ipants who met the inclusion criteria. Data on demo-
graphics, current TB symptoms, TB and HIV history and 
healthcare-seeking behaviour was collected at enrolment. 
Contact attempts and participants’ progress in linkage 
into appropriate care was recorded on log forms.
At the end of the follow-up period, the case managers 
conducted a telephonic or clinic interview with the 
participant to ascertain if linkage into appropriate care 
had taken place by collecting self-reported data on HIV 
testing, TB and ART treatment start dates, health-seeking 
behaviour and current TB symptoms. Additional data 
were collected by professional nurses abstracting from 
clinic records HIV data (such as HIV testing, CD4 count 
testing and ART start dates) and TB data (TB testing and 
treatment start dates). Case report forms were completed 
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on a study-specific smartphone application and data 
submitted in an encrypted format to a central database.4
Description of outcomes and analysis
Linkage into HIV care was defined as at 3 months after 
enrolment: (1) if HIV status unknown at enrolment: 
testing HIV-positive, having done a CD4 count and being 
started on ART if eligible (CD4 count ≤350 cells/mm3 or 
testing Xpert MTB/RIF positive); (2) if HIV-positive with 
an unknown CD4 count and not on ART at enrolment: 
having done a CD4 count test and being started on ART 
if eligible; (3) if last CD4 count done more than 6 months 
previously and not on ART at enrolment: having a CD4 
count done and being started on ART if eligible. Failure 
to initiate ART after 3 months when ART eligible at initial 
assessment was defined as non-linkage to HIV care.
Linkage into TB care (TB treatment initiation) was 
defined as TB treatment start within 28 days of sputum 
submission among patients with a positive sputum test 
result. Non-linkage to TB treatment (pretreatment loss 
to follow-up) was defined as not starting TB treatment 
within 28 days of sputum collection among people with 
a positive TB test result, consistent with definitions in 
previous studies.2 4
Linkage to HIV care or TB treatment initiation was 
confirmed by record of ART or TB treatment start 
date as reported by the participant and documented in 
study documents or from patient clinic files. Mortality 
was ascertained by reports by close relatives or friends 
indicating the death of a participant. Participants were 
defined as lost to follow-up if at 3 months linkage status 
was unknown and the participant could not be contacted 
by case managers.
Contacts attempts were defined as any effort (successful 
or unsuccessful), done either telephonically or inperson 
meeting, made by case managers to interact with a patient. 
The total number of contact attempts per patients was 
counted, and median attempts needed for linkage into 
TB and HIV care or both were calculated.
sample size calculation
This was a pilot study aiming to determine feasibility of 
implementing the intervention and to estimate linkage to 
TB and HIV care. The sample size calculation was based 
on two binary outcomes: (1) uptake of ART among those 
who were HIV positive and ART eligible; (2) pretreatment 
loss to follow-up among those who tested TB positive. We 
had planned to enrol 1200 participants (200 per clinic as 
Figure 1 TB and HIV algorithm used to guide case managers. ART, antiretroviral treatment; DST, Drug-susceptibility testing; 
HCT, HIV Counselling and Testing; MDR, Multi-Drug-resistant; TB, tuberculosis.
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in XTEND) with the assumption that 96 (8%) of those 
tested for TB would test TB positive and need to initiate 
TB treatment.4 We also assumed that 20 (21%) of people 
with a sputum testing positive for TB would experience 
pretreatment loss to follow-up.4 For patients needing 
linkage to HIV care, the assumption was that 240 (20%) 
of patients enrolled would not know their HIV status. It 
was also assumed that 576 (60%) of patients who knew 
their HIV status would self-report being HIV positive.4 
Two hundred and eighty-eight (50%) of those who were 
HIV positive would not know their CD4 count and would 
be ART eligible once a CD4 count test was done.4
risk factor analysis for mortality
Univariable logistic regression analysis was used to assess 
risk factors for mortality. Due to the small proportion of 
participants who died by end of 3-month follow-up, cate-
gories per predictor variable in the univariable model 
were restricted to three and a multivariable logistic 
regression model was not built as a minimum of 10 events 
per predictor variable is required.12 All statistical analyses 
were done using Stata V.14.
Patient and public involvement
Patients or public were not involved in the development 
of research question, outcome measures, study design, 
recruitment to and conduct of the study. Copies of the 
study report will be sent to participants who contact the 
investigators about an interest to receive the study results.
results
baseline characteristics
From September to December 2014, 800 adults having 
a sputum taken for TB investigations in six PHCs were 
screened and 585 were enrolled. Of these 585, 23 from 
one site were excluded from analysis because ill health 
prevented the case manager from undertaking study 
procedures correctly, leaving 562 from five clinics for anal-
ysis. Of the 562 participants, 307 (54.6%) were female, 
and the median age was 36 years (IQR 29–44) (table 1). 
The majority of participants (477, 84.8%) self-reported 
having had an HIV test in the past and of these 328/475 
(69.1%) reported being HIV-positive. Of the 328 HIV-pos-
itive participants, 156/327 (47.7%) reported having 
a CD4 count done within the previous 6 months and 
self-reported median CD4 count was 315 cells/mm3 (IQR 
164–471). Over half of the HIV-positive participants with a 
known CD4 count (209/327 (63.9%)) had never received 
ART. Ninety-six of 562 (17.1%) of the enrolled partici-
pants were previously treated for TB. Five hundred and 
fourteen of 543 (94.7%) participants reported having at 
least one TB symptom to the study team, and the majority 
452/514 (87.9%) reported having cough (table 1).
Implementation of the intervention
Overall, 189/562 (33.6%) participants required linkage 
into HIV care or TB treatment initiation or both. Of the 
Table 1 Baseline characteristics of the study population
Variable n (%) n=562
Gender
  Female 307 (54.6)
Age (median, IQR) 36 (29–44)
Country of birth
  South Africa 447 (79.5)
Ethnic group
  Black 556 (98.9)
Highest education completed
  No schooling 23 (4.0)
  Preschool–Grade 7 124 (22.0)
  Grades 8–12 377 (67.1)
  University/technical qualification 38 (6.8)
Marital status
  Single never married 250 (44.5)
  Married 108 (19.2)
  Cohabitating 159 (28.3)
  Divorced/widowed/separated 45 (8.0)
Main income source
  Formal employment 250 (44.5)
  Self-employment/odd jobs 134 (23.8)
  No income 88 (15.7)
  Grant/dependence 90 (16.0)
Average monthly income
  <ZAR 600 34 (6.0)
  ZAR 601–1000 73 (13.0)
  ZAR 1001–2000 120 (21.4)
  ZAR 2001–4000 167 (29.7)
  Greater than ZAR 4000 58 (10.3)
  Don’t know 110 (19.6)
Ever had HIV test
  Yes 477 (84.9)
Self-reported HIV status (n=475)*
  Negative 143 (30.1)
  Positive 328 (69.1)
  Unknown 4 (0.8)
CD4 count known (n=327)†
  Yes 156 (47.7)
  Self-reported CD4 count, median (IQR) 315 (164–471)
Ever been on ART (n=327)
  Never 209 (63.9)
  Currently 116 (35.5)
  Previously 2 (0.6)
  Time on ART in years, median (IQR) 
n=118
2 (0–4)
Ever treated for TB
Continued
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189, 132/189 (69.8%) participants required linkage into 
HIV care only, 35/189 (18.5%) required TB treatment 
initiation only and 22/189 (11.6%) required both TB 
treatment initiation and linkage to HIV care. A total of 
555 contact attempts were made by the case managers 
to these participants: 310/555 (55.9%) were telephonic, 
243/555 (43.8%) were contacts at clinic and 2/555 
(0.4%) were home visits. Of the 310 telephonic contacts, 
211/310 (68.1%) were successful. Of the 99 unsuccessful 
telephone contact attempts, 98 were due to numbers 
ringing without an answer and in one the call went to 
voicemail.
Contact attempts for linkage to HIV care only
Of the 132 people needing linkage to HIV care only, 407 
contact attempts in total were made to these individuals 
with a median of 3 (IQR 2–4) attempts per individual. 
At the end of the follow-up, 29/132 (22.0%) people had 
still not linked into HIV care, and a total of 111 contact 
attempts, with a median of four attempts (IQR 2–4) per 
individual, had been made to these individuals.
Contact attempts for linkage to TB care only
For people needing to initiate TB treatment only (35), 78 
contact attempts with a median of 2 (IQR 1–3) attempts 
were made. Four (11.4%) of the 35 participants did not 
initiate TB treatment by end of follow-up period. Ten 
contact attempts with median of 1 (IQR 1–4) were made 
to these individuals.
Contact attempts for linkage to TB and HIV care
Seventy contact attempts with median of 3 (IQR 2–4) 
attempts were made to the 22 participants that needed 
both to initiate TB treatment and link into HIV care. At 
end of follow-up, seven (31.8%) of the 22 participants 
had not completely linked into care as they had started 
on TB treatment but had not initiated ART. Twenty-seven 
contact attempts with a median of 2 (IQR 4–5) attempts 
per individual were made to these seven individuals.
linkage into hIV care
Participant flow through the steps of linkage to HIV care 
is shown in figure 2. At enrolment, 94 participants had 
unknown HIV status or a negative HIV test results older 
than 3 months and were offered an HIV test. Among the 
94, 26 (27.7%) declined to test. Of those who tested, 26/68 
(38.2%) were HIV positive. A total of 132 (26 newly tested 
HIV positive and 106 not on ART with unknown CD4 
count) needed a CD4 count, of whom 119/132 (90.2%) 
had blood taken for a CD4 count by the end of the study. 
Of the 135 with a CD4 count result (119 who had a new 
CD4 count and 16 who already knew their CD4 count), 
91/135 (67.4%) were ART eligible and 67/91 (73.6%) of 
those initiated for ART. Of those needing a CD4 count, 
13/132 (9.8%) did not have a CD4 count done and 24/91 
(26.4%) ART eligible did not initiate ART. The highest 
proportion of HIV-positive patients were lost at the ART 
initiation stage (figure 2).
tb treatment initiation
A total of 57/562 (10.1%) participants had a positive 
index Xpert MTB/RIF result. Of the 57, 53 (93.0%) 
started TB treatment within 28 days of testing positive 
for TB with median time to TB treatment initiation of 
5 days (IQR 2–7). Of the four that were not initiated on 
TB treatment, two died before starting TB treatment and 
two started TB treatment more than 28 days after sputum 
was taken. An additional of 22 participants were started 
on TB treatment after being diagnosed by follow-up tests.
We could not do a risk factor analysis for non-linkage 
into care because of the complexity of differing denomi-
nators at different stages of HIV linkage into care and the 
low numbers for those who did not initiate TB treatment.
Mortality and loss to follow-up
At the end of the 3-month follow-up, 27/562 (4.8%) 
participants had died and loss to follow-up was 49/535 
(9.2%). Of the 27 participants who died, 18 had self-re-
ported being HIV positive, and 14/18 (77.8%) of them 
were on ART. Only four of the deceased participants had 
a TB positive index Xpert MTB/RIF result.
risk factors of mortality at 3 months after enrolment
Univariable analysis for mortality (table 2) showed weak 
evidence for an association between having more than 
one TB symptom (OR 2.4, 95% CI 0.89 to 6.45) and 
increased risk of death, but a chance finding cannot be 
excluded.
DIsCussIOn
In our study, 33.6% of people being investigated for TB 
at PHCs in South Africa required linkage into HIV care 
or TB treatment initiation. A high proportion of people 
with positive TB test results started TB treatment with 78 
contact attempts made to them. However, despite support 
with 477 contact attempts from a case manager, a total 
of 21.9% of those needing HIV care only and 31.8% 
Variable n (%) n=562
  Yes 96 (17.1)
TB symptoms reported (n=543)‡
  Yes 514 (94.7)
Symptoms reported (n=514)
  Cough 452 (87.9)
  Unintentional weight loss 311 (60.5)
  Night sweats 218 (42.4) 
  Fever 186 (36.2) 
*Two participants refused to disclose their HIV status.
†Data missing for one participant.
‡Data missing for 19 participants.
ART, antiretroviral treatment; TB, tuberculosis.
Table 1 Continued 
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needing TB and HIV care did not link into HIV care at 
the end of the 3-month follow-up period with the highest 
proportion lost at the ART initiation step. By piloting this 
intervention, we had hoped to overcome obstacles such 
as nurses not having enough time to follow-up patients 
and difficulties of making contact with the patients such 
as clinic phones not working or people having not given 
their contact numbers. The processes of the intervention 
largely worked as intended, with multiple contacts to 
people needing linkage into care. However, HIV linkage 
care was still suboptimal, suggesting that this intervention 
as implemented for HIV was insufficient. It also suggests 
that linkage to HIV care compared with initiation of TB 
treatment is harder to achieve. This is probably due to the 
larger number of steps that were necessary for a person 
to start ART at the time of the study, which included CD4 
count testing for ART eligibility assessments, attendance 
at ART adherence classes and baseline blood tests for 
assessment of contraindications to specific antiretroviral 
drugs. This resulted in patients needing to visit the clinic 
multiple times. South African guidelines now recom-
mend ART for all HIV-positive people regardless of CD4 
count. This may reduce losses along the linkage pathway 
by reducing the number of visits needed.
Some of our study participants refused HIV testing, 
but the proportions (27.7%) in our study were lower 
than that found in a South African study done in 2007 
comparing uptake of HIV test between provider-initiated 
Figure 2 Flow diagram of linkage into HIV care after 3-month follow-up. ART, antiretroviral treatment.
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testing and counselling and provider referral to voluntary 
HIV testing among patients attending community health 
centres.13 The study reported that 45% of patients in the 
provider-initiated testing group, versus 69% of patients 
in voluntary HIV testing group, refused HIV testing.13 In 
a 2012 study, among HIV non-testers from South Africa, 
barriers to testing included fear of knowing one’s HIV 
status and fear of what people may say.14 Linkage to care 
(HIV and TB) in our study was higher compared with 
Sizanani, a randomised control trial in South Africa done 
between 2010 and 2013 using health navigators sending 
short messaging service reminders to newly diagnosed 
HIV-positive people to link into TB and HIV care.10 This 
difference is probably because linkage to care was defined 
differently in Sizanani compared with our study. Stan-
dardised definitions of linkage to care would facilitate 
making comparisons and setting standards.10
A number of participants in our study declined to 
start on ART because they could not get time off work. 
This could be because the health system is too difficult 
or time-consuming for working people to navigate; it 
could also be that participants not wanting to start ART 
for other reasons gave this as an excuse for not returning 
to the clinic. A study determining rates and predictors 
of declining to start ART in treatment-eligible HIV-posi-
tive individuals in South Africa in 2009 showed that 20% 
refused to start ART and 37% of those reported feeling 
healthy as a reason for non-initiation.15 Another study, 
from South Africa in 2010, showed that stigma was the 
main barrier to initiating ART.16 The limited information 
available around the reasons for non-linkage to HIV care 
suggest that the problem is not simply a failure of clinic 
staff to communicate results but rather a multifactorial 
challenge with health system, individual and structural 
components.10
Some interventions have had successes in improving 
linkage to care. A study in Uganda focusing on improving 
processes within clinics showed an improvement in ART 
initiation among HIV-positive patients.17 Another study 
done in Zambia and Tanzania that combined clinic-based 
care plus community support showed a reduction in 
mortality in HIV-positive patients compared with standard 
of care.18 It is hard to know what exactly made these inter-
ventions work, but the Ugandan study differed from our 
study in that it targeted multiple number of components 
within the clinic such as staff training, coaching and facility 
feedback. However, the Zambian and Tanzanian study 
differed in that community support was provided by a lay 
worker with a higher qualification than a lay counsellor and 
trained on monitoring of patients for disease progression 
as well as drug toxicity. Our intervention tried to address 
challenges of communication between clinic and patients 
as well as provide support and encouragement to patients.
Our data showed that among adults with a positive 
Xpert MTB/RIF sputum result, 93.0% were started on TB 
treatment with 148 contact attempts made to them. The 
median time to TB treatment start in our study was 5 days, 
which is within the recommended national department 
of health target of 2–5 days.6 We could not quantify the 
total number of participants who were diagnosed with 
TB using follow-up tests in our study, as some may have 
started TB treatment after our follow-up ended. Pretreat-
ment loss to follow-up was lower than the 11%–25% found 
in previous studies in South Africa, although comparisons 
are limited by the relatively small numbers in our study.1–4
Mortality was high in our study at 4.8% by 3 months 
suggesting that people are presenting with advanced 
disease or when already severely ill. This underscores the 
importance of early diagnosis and linkage to care.
Strengths of our study include prospectively enrolling 
a representative sample of adults being investigated for 
TB from five clinics in two provinces of the country that 
are diverse in living conditions and population and likely 
to be representative of urban and periurban practice in 
South Africa. A limitation of our study is that this was a 
pilot study and as such had no ‘standard of care’ compar-
ison group; therefore, we cannot formally determine if 
the strategy made a difference or not. Another limitation 
is that we did not keep record of TB treatment started 
after the follow-up period.
COnClusIOn
In our pilot study assessing the potential effect of a 
case manager to support linkage into HIV care and TB 
Table 2 Univariate analysis for risk factors for mortality
Variable
Proportion 
died (%) OR (95% CI)
P 
values
Gender
  Male 10/255 (3.9) 1
  Female 17/307 (5.5) 1.43 (0.65 to 3.19)   0.37
Age group
  >30 5/144 (3.5) 1
  30–39.9 14/210 (6.7) 1.99 (0.69 to 5.64)
  ≤40 8/208 (3.8) 1.11 (0.36 to 3.47)   0.29
Self-reported HIV status
  Negative 5/130 (3.8) 1
  HIV-positive 
on ART
4/120 (3.3) 0.86 (0.23 to 3.28)
  HIV-positive 
not on ART
14/205 (6.8) 1.83 (0.64 to 5.21)   0.29
Number of TB symptoms
  ≤1 5/194 (2.6) 1
  2 and more 22/368 (6.0) 2.4 (0.89 to 6.45)   0.05
BMI
  <18.5 4/78 (5.1) 0.88 (0.29 to 2.68)
  18.5–24.9 18/311 (5.8) 1
  25+ 5/173 (2.9) 0.48 (0.18 to 1.32)   0.33
 ART, antiretroviral treatment; BMI, body mass index; TB, 
tuberculosis.
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treatment initiation among adults being investigated for 
TB, we report a higher than desirable rate of non-linkage 
into HIV care. This is an indication that the piloted 
strategy lacks components that are crucial to the successful 
engagement of patients into HIV care. A qualitative eval-
uation of the intervention (in progress) may give insights 
into how this intervention could be improved. This pilot 
study was planned with the intention to conduct a larger 
trial afterwards, but our findings suggest that further 
work be done before the intervention is further evalu-
ated. We recommend that more innovative approaches 
be explored to find strategies that will improve linkage to 
HIV care and TB treatment initiation in this population 
to reduce mortality.
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